Trial halted for new uterine cancer treatment combo
NCT ID NCT05481645
Summary
This study tested a new combination of drugs for people with advanced endometrial cancer or uterine sarcoma who had not yet received treatment. The treatment involved an immunotherapy drug (TQB2450) plus standard chemotherapy, with or without another targeted drug (anlotinib), followed by maintenance therapy. The main goal was to see how well the tumors shrank and how safe the treatment was. The trial was terminated and enrolled 71 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED ENDOMETRIAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Hunan Cancer Hospital
Changsha, Hunan, 410013, China
-
Liaoning Cancer Hospital & Institute
Shenyang, Liaoning, 110801, China
-
Linyi Cancer Hospital
Linyi, Shandong, 276002, China
-
Obstetrics & Gynecology Hospital of Fudan University
Shanghai, Shanghai Municipality, 200090, China
-
Shandong Cancer Hospital
Jinan, Shandong, 250117, China
-
Sun Yat-sen Memorial Hospital
Guangzhou, Guangdong, 510120, China
-
Taizhou People's Hospital
Taizhou, Jiangsu, 225399, China
-
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, 710061, China
-
TianJin Medical University Cancer Institute & Hopspital
Tianjin, Tianjin Municipality, 300181, China
-
Yantai Yuhuangding Hospital
Yantai, Shandong, 264099, China
-
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, 430062, China
Conditions
Explore the condition pages connected to this study.